Tango Therapeutics Files 8-K for Financials
Ticker: TNGX · Form: 8-K · Filed: Mar 18, 2024 · CIK: 1819133
Sentiment: neutral
Topics: financial-condition, financial-statements, filing
Related Tickers: TNGX
TL;DR
Tango Therapeutics dropped an 8-K on March 18th detailing their financials. Check it out.
AI Summary
Tango Therapeutics, Inc. filed an 8-K on March 18, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The company, previously known as BCTG Acquisition Corp. until July 23, 2020, is incorporated in Delaware and headquartered in Boston, MA.
Why It Matters
This filing provides crucial updates on Tango Therapeutics' financial health and operational status, which are important for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Tango Therapeutics, Inc. (company) — Registrant
- BCTG Acquisition Corp. (company) — Former company name
- March 18, 2024 (date) — Filing date
- 201 Brookline Avenue, Suite 901, Boston, MA 02215 (location) — Principal executive offices address
FAQ
What is the primary purpose of this 8-K filing for Tango Therapeutics?
The primary purpose of this 8-K filing is to report on Tango Therapeutics' results of operations and financial condition, and to file financial statements and exhibits.
When was Tango Therapeutics, Inc. previously known by another name?
Tango Therapeutics, Inc. was formerly known as BCTG Acquisition Corp. until July 23, 2020.
In which state is Tango Therapeutics, Inc. incorporated?
Tango Therapeutics, Inc. is incorporated in Delaware.
What is the business address of Tango Therapeutics, Inc.?
The business address of Tango Therapeutics, Inc. is 201 Brookline Avenue, Suite 901, Boston, MA 02215.
What is the telephone number for Tango Therapeutics, Inc.?
The telephone number for Tango Therapeutics, Inc. is (857) 320-4900.
Filing Stats: 546 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-03-18 07:08:45
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TNGX The Nasdaq Global
Filing Documents
- tngx-20220810.htm (8-K) — 41KB
- tngx-ex99_1.htm (EX-99.1) — 185KB
- img21139354_0.jpg (GRAPHIC) — 26KB
- img159114951_0.jpg (GRAPHIC) — 1KB
- 0000950170-24-032513.txt ( ) — 421KB
- tngx-20220810.xsd (EX-101.SCH) — 48KB
- tngx-20220810_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 18, 2024, Tango Therapeutics, Inc. (Tango or the Company) issued a press release relating to its results of operations and financial condition for the quarter and year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The press release, and the information set forth therein (including Exhibit 99.1), is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that Section. Nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in the filing unless specifically stated so therein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No . Description 99.1 Press Release issued by Tango Therapeutics, Inc. on March 18, 2024 relating to its results of operations and financial condition for the quarter ended December 31, 2023. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TANGO THERAPEUTICS, INC. Dated: March 18, 2024 By: /s/ Douglas Barry Name: Douglas Barry Title: General Counsel